Covered recipient · General Payments record
KARINA MICHELLE AROCHO-GONZALEZ
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2023 · Entire year
$1,313.93
53 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2023 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,228.94 | 52 |
| Education | $84.99 | 1 |
By paying entity
PY2023 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| PBG PUERTO RICO LLC | $173.96 | 9 |
| CTI BioPharma Corp. | $145.06 | 1 |
| E.R. Squibb & Sons, L.L.C. | $126.47 | 6 |
| Amgen Inc. | $126.38 | 6 |
| Merck Sharp & Dohme LLC | $101.00 | 5 |
| AbbVie Inc. | $89.60 | 4 |
| Exelixis Inc. | $84.99 | 1 |
| Janssen Pharmaceuticals, Inc | $71.89 | 3 |
| Genentech USA, Inc. | $67.66 | 3 |
| AstraZeneca Pharmaceuticals LP | $67.00 | 3 |
| Verity Pharmaceuticals Inc. | $48.34 | 2 |
| Novartis Pharmaceuticals Corporation | $45.01 | 2 |
| Eli Lilly Export S.A. Puerto Rico Branch | $36.18 | 2 |
| Rigel Pharmaceuticals, Inc. | $25.55 | 1 |
| GENZYME CORPORATION | $24.95 | 1 |
| Eisai Inc. | $21.95 | 1 |
| EMD Serono, Inc. | $20.40 | 1 |
| Gilead Sciences, Inc. | $20.29 | 1 |
| SOBI, INC | $17.25 | 1 |
Page 2 of 2; records 51–53 of 53 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
KARINA MICHELLE AROCHO-GONZALEZ
NPI 1851724512 · CMS profile ID 84512
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
HATO REY, PR
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–53 of 53 matching records. This page contains 3 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1851724512?year=2023&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- KARINA MICHELLE AROCHO-GONZALEZ, NPI 1851724512, CMS profile ID 84512. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–53 of 53 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1851724512?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- APA 7
- IndustryPayments. (2026). KARINA MICHELLE AROCHO-GONZALEZ, NPI 1851724512, CMS profile ID 84512. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–53 of 53 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1851724512?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- Bluebook
- KARINA MICHELLE AROCHO-GONZALEZ, NPI 1851724512, CMS profile ID 84512, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–53 of 53 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1851724512?year=2023&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30
53 matching records · $1,313.93 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–53 of 53.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $20.00 | 01/26/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015632983 | CMS |
| Genentech USA, Inc. | $25.00 | 01/19/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1040422417 | CMS |
| Eli Lilly Export S.A. Puerto Rico Branch | $16.95 | 01/12/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031751035 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $616,228.10 | 34 |
| PY2024 | Principal investigator | $482,406.90 | 48 |
| PY2023 | Principal investigator | $25,675.00 | 2 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
34 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | PFIZER INC. | $106,526.40 | 12/09/2025 | Non-covered Recipient Entity Pan American Center for Oncology Trials LLC | AN INTERVENTIONAL OPENLABEL PHASE 1B2 STUDY TO EVALUATE SAFETY PHARMACOKINETICS AND PRELIMINARY EFFICACY OF PF08634404 AS MONOTHERAPY AND COMBINATION THERAPY IN ADULT PARTICIPANTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA | No dispute reported | 06/30/2026 | 1228721249 |
| Principal investigator 1 | Genentech, Inc. | $23,172.00 | 12/02/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | ATEZOLIZUMAB AND BEVACIZUMAB TIRAGOLUMAB IN 1L UNRESECTABLE HCC PTS | No dispute reported | 06/30/2026 | 1211636688 |
| Principal investigator 1 | Janssen Research & Development, LLC | $375.00 | 11/20/2025 | Non-covered Recipient Entity Pan Amercn Ctr For Oncology Trials Llc | A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) | No dispute reported | 06/30/2026 | 1175268748 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,375.00 | 11/20/2025 | Non-covered Recipient Entity Pan Amercn Ctr For Oncology Trials Llc | A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) | No dispute reported | 06/30/2026 | 1175268756 |
| Principal investigator 1 | Janssen Research & Development, LLC | $375.00 | 11/20/2025 | Non-covered Recipient Entity Pan Amercn Ctr For Oncology Trials Llc | A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) | No dispute reported | 06/30/2026 | 1175268764 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,750.00 | 11/20/2025 | Non-covered Recipient Entity Pan Amercn Ctr For Oncology Trials Llc | A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) | No dispute reported | 06/30/2026 | 1175268771 |
| Principal investigator 1 | Janssen Research & Development, LLC | $375.00 | 11/20/2025 | Non-covered Recipient Entity Pan Amercn Ctr For Oncology Trials Llc | A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) | No dispute reported | 06/30/2026 | 1175268787 |
| Principal investigator 1 | Janssen Research & Development, LLC | $375.00 | 11/20/2025 | Non-covered Recipient Entity Pan Amercn Ctr For Oncology Trials Llc | A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) | No dispute reported | 06/30/2026 | 1175268795 |
| Principal investigator 1 | Janssen Research & Development, LLC | $375.00 | 11/20/2025 | Non-covered Recipient Entity Pan Amercn Ctr For Oncology Trials Llc | A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) | No dispute reported | 06/30/2026 | 1175268802 |
| Principal investigator 1 | Janssen Research & Development, LLC | $375.00 | 11/20/2025 | Non-covered Recipient Entity Pan Amercn Ctr For Oncology Trials Llc | A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) | No dispute reported | 06/30/2026 | 1175268816 |
| Principal investigator 1 | Janssen Research & Development, LLC | $500.00 | 11/20/2025 | Non-covered Recipient Entity Pan Amercn Ctr For Oncology Trials Llc | A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) | No dispute reported | 06/30/2026 | 1175268831 |
| Principal investigator 1 | Janssen Research & Development, LLC | $375.00 | 11/20/2025 | Non-covered Recipient Entity Pan Amercn Ctr For Oncology Trials Llc | A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) | No dispute reported | 06/30/2026 | 1175268839 |
| Principal investigator 1 | Janssen Research & Development, LLC | $375.00 | 11/20/2025 | Non-covered Recipient Entity Pan Amercn Ctr For Oncology Trials Llc | A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) | No dispute reported | 06/30/2026 | 1175268844 |
| Principal investigator 1 | Genentech, Inc. | $23,329.00 | 11/14/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | ATEZOLIZUMAB AND BEVACIZUMAB TIRAGOLUMAB IN 1L UNRESECTABLE HCC PTS | No dispute reported | 06/30/2026 | 1211636684 |
| Principal investigator 1 | BeOne Medicines Ltd. | $11,148.00 | 11/11/2025 | Non-covered Recipient Entity Pan American Oncology Trials, LLC | A Phase 3, Multi-Center, Randomized, Open-Label Clinical Study of Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | No dispute reported | 06/30/2026 | 1190342829 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $25,129.00 | 09/30/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | a randomized,phase third study of rilvegostomig in combination with fluoropyrimidine and trastuzumab deruxtecan versus trastuzumab,chemotherapy,and pembrolizumab for the first line treatment of positive gastric cancer | No dispute reported | 06/30/2026 | 1185551231 |
| Principal investigator 1 | BeOne Medicines Ltd. | $11,148.00 | 09/12/2025 | Non-covered Recipient Entity Pan American Oncology Trials, LLC | A Phase 3, Multi-Center, Randomized, Open-Label Clinical Study of Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | No dispute reported | 06/30/2026 | 1190342777 |
| Principal investigator 1 | BeOne Medicines Ltd. | $22,296.00 | 09/12/2025 | Non-covered Recipient Entity Pan American Oncology Trials, LLC | A Phase 3, Multi-Center, Randomized, Open-Label Clinical Study of Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | No dispute reported | 06/30/2026 | 1190342780 |
| Principal investigator 1 | Genentech, Inc. | $28,568.00 | 09/08/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | ATEZOLIZUMAB AND BEVACIZUMAB TIRAGOLUMAB IN 1L UNRESECTABLE HCC PTS | No dispute reported | 06/30/2026 | 1211636677 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $4,045.00 | 09/05/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | A Phase 3 Study, Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab with Standard-of-Care Therapy Against Standard-of-Care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer. | No dispute reported | 06/30/2026 | 1233741650 |
| Principal investigator 1 | Genentech, Inc. | $25,675.00 | 09/04/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | ATEZOLIZUMAB AND BEVACIZUMAB TIRAGOLUMAB IN 1L UNRESECTABLE HCC PTS | No dispute reported | 06/30/2026 | 1211636679 |
| Principal investigator 1 | Genentech, Inc. | $2,087.00 | 07/18/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211636726 |
| Principal investigator 1 | Genentech, Inc. | $74,705.00 | 07/09/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | ATEZOLIZUMAB AND BEVACIZUMAB TIRAGOLUMAB IN 1L UNRESECTABLE HCC PTS | No dispute reported | 06/30/2026 | 1211636672 |
| Principal investigator 1 | Genentech, Inc. | $59,366.00 | 06/10/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | ATEZOLIZUMAB AND BEVACIZUMAB TIRAGOLUMAB IN 1L UNRESECTABLE HCC PTS | No dispute reported | 06/30/2026 | 1211636651 |
| Principal investigator 1 | Genentech, Inc. | $39,390.00 | 05/09/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | ATEZOLIZUMAB AND BEVACIZUMAB TIRAGOLUMAB IN 1L UNRESECTABLE HCC PTS | No dispute reported | 06/30/2026 | 1211636667 |
| Principal investigator 1 | Genentech, Inc. | $2,500.00 | 05/01/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211636714 |
| Principal investigator 1 | Genentech, Inc. | $1,450.00 | 05/01/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211636718 |
| Principal investigator 1 | Genentech, Inc. | $8,820.70 | 02/12/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211636706 |
| Principal investigator 1 | Genentech, Inc. | $75.00 | 02/12/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211636710 |
| Principal investigator 1 | Genentech, Inc. | $12,453.00 | 02/05/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211636697 |
| Principal investigator 1 | Genentech, Inc. | $75.00 | 02/05/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211636701 |
| Principal investigator 1 | Genentech, Inc. | $689.00 | 01/21/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | ATEZOLIZUMAB AND BEVACIZUMAB TIRAGOLUMAB IN 1L UNRESECTABLE HCC PTS | No dispute reported | 06/30/2026 | 1211636659 |
| Principal investigator 1 | Genentech, Inc. | $71,717.00 | 01/17/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | ATEZOLIZUMAB AND BEVACIZUMAB TIRAGOLUMAB IN 1L UNRESECTABLE HCC PTS | No dispute reported | 06/30/2026 | 1211636654 |
| Principal investigator 1 | Genentech, Inc. | $55,239.00 | 01/14/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | ATEZOLIZUMAB AND BEVACIZUMAB TIRAGOLUMAB IN 1L UNRESECTABLE HCC PTS | No dispute reported | 06/30/2026 | 1211636663 |